Profile_LisaPettingill.jpg

Lisa N. Gillespie (previously Pettingill)

BSc (Hons) (Monash University), PhD (The University of Melbourne)

Research Fellow, Bionics Institute

P: +61 3 9288 2974
E: lgillespie@bionicsinstitute.org

Dr Gillespie's research interests revolve around the potential of neurotrophic factors for survival and repair in neurodegenerative conditions. She received her B. Sci. (Honours) degree in 1997 from Monash University for a project investigating neurotrophic support of denervated spinal cord, and received her PhD from the University of Melbourne in 2004 for research investigating the potential of neurotrophic factors to protect the inner ear from the degenerative changes that occur in deafness.

Dr Gillespie's post-doctoral studies are investigating the use of gene and cell-therapy techniques designed to deliver neurotrophins to the deaf cochlea, in conjunction with simultaneous cochlear implantation, to prevent deafness-associated auditory neuron degeneration. This work is being performed with Professor Rob Shepherd (Bionics Institute) and Professor Alan Harvey, from the University of Western Australia.

Research fields of interest

  • Protection of auditory neurons from degeneration in deafness
  • Genetic manipulations for neurotrophin production
  • Cell-based delivery of neurotrophins
  • Cellular encapsulation
  • Combined effects of cell-based neurotrophin treatment and cochlear implantation

Research projects

Publications

  1. Pettingill LN, Minter RL and Shepherd RK (2008). Schwann cells genetically modified to express neurotrophins promote spiral ganglion neuron survival in vitro. Neuroscience 152(3) : 821-8.

  2. Pettingill LN, Richardson RT, Wise AK, O’Leary S and Shepherd RK (2007). Neurotrophic factors and neural prostheses: potential clinical applications based upon findings in the auditory system. IEEE Transactions on Biomedical Engineering 54 : 1138-1148.

  3. Wise AK, Pettingill LN and Richardson RT (2007). Neurofilament proteins in the cochlea: Changes in response to deafening and neurotrophin administration. In: Arlen R.K. (ed). New Research on Neurofilament Proteins. Nova Science Publishers Inc., New York. pp: 1-24.

  4. B Coleman, JB Fallon, LN Gillespie LN and Shepherd RK (2005). Clinical application of neurotrophic factors: the potential for primary auditory neuron protection. European Journal of Neuroscience 22(9): 2123-2133.

  5. Gillespie LN , Clark GM, Marzella PL and Crook JM (2005). Netrin-1 as a guidance molecule in the postnatal mammalian cochlea. Hearing Research 199: 117-123.

  6. Gillespie LN, Clark GM, Marzella PL (2004). Delayed neurotrophin treatment supports auditory neuron survival in deaf guinea pigs. NeuroReport 15(7) : 1121-1125.

  7. Gillespie LN (2003). Brief Review: Regulation of axonal growth and guidance by the neurotrophin family of neurotrophic factors. Clinical and Experimental Pharmacology and Physiology 30(10) : 724-33.

  8. Gillespie LN, Clark GM, Bartlett PF & Marzella PL (2003). BDNF-induced survival of auditory neurons in vivo: Cessation of treatment leads to accelerated loss of survival effects. Journal of Neuroscience Research 71(6): 785-790

  9. Marzella PL & Gillespie LN (2002). Brief Review: Role of trophic factors in the development, survival and repair of primary auditory neurons. Clinical and Experimental Pharmacology and Physiology 29(5-6):363-371.

See more publications by Dr Lisa Gillepsie (Pettingill) in PubMed

 

Sign In